Arena's Real Issue: Drugs Vs. Gym & Behavior Modification (ARNA)

Health and Healthcare

Published: March 30, 2009 8:36 am

Last Updated: April 27, 2020 4:32 pm

burning-money-pic40 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is getting shelled this morning. The company released “positive study data” this morning on trials for its obesity treatment Lorcaserin. But the real issue around the results is that it looks like the Wall Street answer is just “That’s it?”….

Arena’s positive top-line results from its behavioral modification and Lorcaserin for overweight and obesity management is the first of two pivotal trials evaluating the safety and efficacy for weight loss and weight management. The company noted that statistical significance was achieved on all three of the co-primary endpoints versus placebo. The endpoints were the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months.

The study showed that 47.5% of Lorcaserin patients lost greater than or equal to 5% of their body weight from the baseline, compared to 20.3% in the placebo group.

Average weight loss of 5.8% of body weight, or 12.7 pounds, was achieved in the Lorcaserin group, compared to 2.2% of body weight, or 4.7 pounds, in the placebo group.

The study said 22.6% of Lorcaserin patients lost greater than or equal to 10% of their body weight from the baseline, compared to 7.7% in the placebo group.

There is just one problem with these results in the “That’s it?” thesis. Going to a weight management seminar even once per month and using an exercise regimen at a gym should be able to do better than this. Unless someone is too fat to exercise or too out of shape to exercise, then there are no real side effects compared to any drug.

Shares are getting hit by 30% at $3.17 right before the open. The 52-week range is $2.70 to $7.42.

In the world of obesity treatment via drugs, the world is looking for that major weight-loss pill rather than an incremental boost from a pill. Again, the gym and a once a month class could produce better results… assuming the person wants to lose weight and is willing to engage in behavior modification.

JON C. OGG
March 30, 2009

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.